We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-8.66%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$419M
AUM Growth
-$20.7M
Cap. Flow
+$25.1M
Cap. Flow %
5.99%
Top 10 Hldgs %
47.79%
Holding
85
New
13
Increased
17
Reduced
18
Closed
2

Top Buys

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$8.5M
2
URGN icon
UroGen Pharma
URGN
+$6.67M
3
BHVN icon
Biohaven
BHVN
+$3.95M
4
ALKS icon
Alkermes
ALKS
+$2.96M
5
SLRN
ACELYRIN
SLRN
+$2.3M

Top Sells

Rank Stock Value
1
PRCT icon
Procept Biorobotics
PRCT
+$2.44M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$2.25M
3
BNTX icon
BioNTech
BNTX
+$1.57M
4
ASND icon
Ascendis Pharma A/S
ASND
+$1.56M
5
CATX icon
Perspective Therapeutics
CATX
+$1.14M

Sector Composition

Rank Sector Weight
1 Healthcare 85.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORIC icon
76
Oric Pharmaceuticals
ORIC
$1.1B
$255K 0.06%
+36,000
New +$322K
FHTX icon
77
Foghorn Therapeutics
FHTX
$271M
$241K 0.06%
+41,850
New +$249K
NVRO
78
DELISTED
NEVRO CORP.
NVRO
$236K 0.06%
28,000
– –
GPCR icon
79
Structure Therapeutics
GPCR
$3.44B
$196K 0.05%
+5,000
New +$205K
KPTI icon
80
Karyopharm Therapeutics
KPTI
$44.6M
$167K 0.04%
12,845
– –
SPRO icon
81
Spero Therapeutics
SPRO
$66.6M
$163K 0.04%
125,000
– –
CMPX icon
82
Compass Therapeutics
CMPX
$339M
$117K 0.03%
116,882
– –
BNTX icon
83
BioNTech
BNTX
$23.3B
– –
-17,000
Closed -$1.57M
VIGL
84
DELISTED
Vigil Neuroscience
VIGL
– –
-71,815
Closed -$245K
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return

DAFNA Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, DAFNA Capital Management held 85 positions worth $419M, down 4.7% from $439M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management deployed $25.1M of net new capital in Q2 2024, opening 13 new positions and adding to 17 existing holdings. Its largest new stake was UroGen Pharma: 469,000 shares worth $7.87M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Procept Biorobotics, an estimated $2.44M trimmed.

  • DAFNA Capital Management's largest Q2 2024 buy was UroGen Pharma: 469,000 shares worth $7.87M.
  • DAFNA Capital Management added most to AtriCure in Q2 2024, an estimated $8.5M increase.
  • DAFNA Capital Management's biggest Q2 2024 reduction was Procept Biorobotics, cutting an estimated $2.44M.
  • DAFNA Capital Management fully exited BioNTech in Q2 2024, selling an estimated $1.57M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $419M portfolio in Q2 2024.
  • DAFNA Capital Management opened 13 new positions and closed 2 in Q2 2024.
  • DAFNA Capital Management's portfolio value fell 4.7% quarter-over-quarter to $419M.

Based on DAFNA Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.